169 related articles for article (PubMed ID: 23393143)
1. Engineering anthrax toxin variants that exclusively form octamers and their application to targeting tumors.
Phillips DD; Fattah RJ; Crown D; Zhang Y; Liu S; Moayeri M; Fischer ER; Hansen BT; Ghirlando R; Nestorovich EM; Wein AN; Simons L; Leppla SH; Leysath CE
J Biol Chem; 2013 Mar; 288(13):9058-65. PubMed ID: 23393143
[TBL] [Abstract][Full Text] [Related]
2. Bismaleimide cross-linked anthrax toxin forms functional octamers with high specificity in tumor targeting.
Fischer ES; Campbell WA; Liu S; Ghirlando R; Fattah RJ; Bugge TH; Leppla SH
Protein Sci; 2019 Jun; 28(6):1059-1070. PubMed ID: 30942916
[TBL] [Abstract][Full Text] [Related]
3. Role of the protective antigen octamer in the molecular mechanism of anthrax lethal toxin stabilization in plasma.
Kintzer AF; Sterling HJ; Tang II; Abdul-Gader A; Miles AJ; Wallace BA; Williams ER; Krantz BA
J Mol Biol; 2010 Jun; 399(5):741-58. PubMed ID: 20433851
[TBL] [Abstract][Full Text] [Related]
4. Molecular dynamics simulations of complexes between wild-type and mutant anthrax protective antigen variants and a model anthrax toxin receptor.
Stiles L; Nelson DJ
J Biomol Struct Dyn; 2005 Apr; 22(5):503-19. PubMed ID: 15702923
[TBL] [Abstract][Full Text] [Related]
5. Anthrax toxin receptor drives protective antigen oligomerization and stabilizes the heptameric and octameric oligomer by a similar mechanism.
Kintzer AF; Sterling HJ; Tang II; Williams ER; Krantz BA
PLoS One; 2010 Nov; 5(11):e13888. PubMed ID: 21079738
[TBL] [Abstract][Full Text] [Related]
6. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
Yan M; Roehrl MH; Basar E; Wang JY
Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
[TBL] [Abstract][Full Text] [Related]
7. Identification of new dominant-negative mutants of anthrax protective antigen using directed evolution.
Wu G; Feng C; Cao S; Guo A; Liu Z
Appl Biochem Biotechnol; 2012 Nov; 168(5):1302-10. PubMed ID: 22948605
[TBL] [Abstract][Full Text] [Related]
8. Cryo-EM structure of the fully-loaded asymmetric anthrax lethal toxin in its heptameric pre-pore state.
Antoni C; Quentin D; Lang AE; Aktories K; Gatsogiannis C; Raunser S
PLoS Pathog; 2020 Aug; 16(8):e1008530. PubMed ID: 32810181
[TBL] [Abstract][Full Text] [Related]
9. Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin.
Liu S; Redeye V; Kuremsky JG; Kuhnen M; Molinolo A; Bugge TH; Leppla SH
Nat Biotechnol; 2005 Jun; 23(6):725-30. PubMed ID: 15895075
[TBL] [Abstract][Full Text] [Related]
10. Self-association of the transmembrane domain of an anthrax toxin receptor.
Go MY; Kim S; Partridge AW; Melnyk RA; Rath A; Deber CM; Mogridge J
J Mol Biol; 2006 Jun; 360(1):145-56. PubMed ID: 16756998
[TBL] [Abstract][Full Text] [Related]
11. Role of toxin functional domains in anthrax pathogenesis.
Brossier F; Weber-Levy M; Mock M; Sirard JC
Infect Immun; 2000 Apr; 68(4):1781-6. PubMed ID: 10722564
[TBL] [Abstract][Full Text] [Related]
12. Purified Bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity.
Panchal RG; Halverson KM; Ribot W; Lane D; Kenny T; Abshire TG; Ezzell JW; Hoover TA; Powell B; Little S; Kasianowicz JJ; Bavari S
J Biol Chem; 2005 Mar; 280(11):10834-9. PubMed ID: 15644338
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.
Abboud N; Casadevall A
Clin Vaccine Immunol; 2008 Jul; 15(7):1115-23. PubMed ID: 18480236
[TBL] [Abstract][Full Text] [Related]
14. Complement C3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response.
Kolla RV; Chintalapati S; Sabet M; Santelli E; Liddington RC; David M; Fierer J; Guiney D; Rickert RC
PLoS One; 2007 Oct; 2(10):e1044. PubMed ID: 17940608
[TBL] [Abstract][Full Text] [Related]
15. A receptor-based switch that regulates anthrax toxin pore formation.
Pilpa RM; Bayrhuber M; Marlett JM; Riek R; Young JA
PLoS Pathog; 2011 Dec; 7(12):e1002354. PubMed ID: 22174672
[TBL] [Abstract][Full Text] [Related]
16. The Disulfide Bond Cys255-Cys279 in the Immunoglobulin-Like Domain of Anthrax Toxin Receptor 2 Is Required for Membrane Insertion of Anthrax Protective Antigen Pore.
Jacquez P; Avila G; Boone K; Altiyev A; Puschhof J; Sauter R; Arigi E; Ruiz B; Peng X; Almeida I; Sherman M; Xiao C; Sun J
PLoS One; 2015; 10(6):e0130832. PubMed ID: 26107617
[TBL] [Abstract][Full Text] [Related]
17. Membrane translocation by anthrax toxin.
Collier RJ
Mol Aspects Med; 2009 Dec; 30(6):413-22. PubMed ID: 19563824
[TBL] [Abstract][Full Text] [Related]
18. Anthrax toxin: the long and winding road that leads to the kill.
Abrami L; Reig N; van der Goot FG
Trends Microbiol; 2005 Feb; 13(2):72-8. PubMed ID: 15680766
[TBL] [Abstract][Full Text] [Related]
19. Changing the receptor specificity of anthrax toxin.
Mechaly A; McCluskey AJ; Collier RJ
mBio; 2012; 3(3):. PubMed ID: 22550037
[TBL] [Abstract][Full Text] [Related]
20. Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells.
Chen KH; Liu S; Bankston LA; Liddington RC; Leppla SH
J Biol Chem; 2007 Mar; 282(13):9834-9845. PubMed ID: 17251181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
